Pfizer (PFE) is in talks to merge its off-patent drugs business with Mylan (MYL) and a deal could be announced as soon as Monday, Jonathan Rockoff and Cara Lombardo of Wall Street Journal report, citing people familiar with the matter.
Mylan shareholders would own a little more than 40% of the new entity and Pfizer shareholders the remainder, a source told the Journal. Pfizer would also receive about $12B in proceeds from a new sale of debt, the source added. Michael Goettler, who runs Pfizer's off-patent drugs business, would become CEO of the combined company, and Mylan Chairman Robert Coury would be Executive Chairman, one of the people said.
Comments
Log in or sign up to join the conversation.